Interleukin-4 receptor-targeted liposomal doxorubicin as a model for enhancing cellular uptake and antitumor efficacy in murine colorectal cancer

Chih Yung Yang, Hong Wen Liu, Ya Ching Tsai, Ju Yu Tseng, Shu Ching Liang, Chin Yau Chen, Wei Nan Lian, Ming Cheng Wei, Maggie Lu, Ruey Hwa Lu, Chi Hung Lin, Jeng Kai Jiang*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

Our previous studies showed that colorectal tumor has high interleukin-4 receptor α (IL-4Rα) expression, whereas adjacent normal tissue has low or no IL-4Rα expression. We also observed that human atherosclerotic plaque-specific peptide-1 (AP1) can specifically target to IL-4Rα. In this study, we investigated the therapeutic efficacy and systemic toxicity of AP1-conjuagted liposomal doxorubicin. AP1 bound more strongly to and was more efficiently internalized into IL-4Rα-overexpressing CT26 cells than CT26 control cells. Selective cytotoxicity experiment revealed that AP1-conjugated liposomal doxorubicin preferentially killed IL-4Rα-overexpressing CT26 cells. AP1-conjugated liposomal doxorubicin administered intravenously into mice produced significant inhibition of tumor growth and showed decreased cardiotoxicity of doxorubicin. These results indicated that AP1-conjugated liposomal doxorubicin has a potent and selective anticancer potential against IL-4Rα-overexpressing colorectal cancer cells, thus providing a model for targeted anticancer therapy.

Original languageEnglish
Pages (from-to)1641-1650
Number of pages10
JournalCancer Biology and Therapy
Volume16
Issue number11
DOIs
StatePublished - 30 Oct 2015

Keywords

  • AP1
  • colorectal cancer
  • interleukin-4 receptor α
  • targeted drug delivery

Fingerprint Dive into the research topics of 'Interleukin-4 receptor-targeted liposomal doxorubicin as a model for enhancing cellular uptake and antitumor efficacy in murine colorectal cancer'. Together they form a unique fingerprint.

Cite this